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Stability of gene expression and epigenetic profiles
highlights the utility of patient-derived paediatric
acute lymphoblastic leukaemia xenografts for
investigating molecular mechanisms of drug
resistance
Nicholas C Wong1,2,4†, Vivek A Bhadri3†, Jovana Maksimovic1, Mandy Parkinson-Bates1, Jane Ng1, Jeff M Craig1,4,
Richard Saffery1,4† and Richard B Lock3*†
Abstract
Background: Patient-derived tumour xenografts are an attractive model for preclinical testing of anti-cancer drugs.
Insights into tumour biology and biomarkers predictive of responses to chemotherapeutic drugs can also be gained
from investigating xenograft models. As a first step towards examining the equivalence of epigenetic profiles
between xenografts and primary tumours in paediatric leukaemia, we performed genome-scale DNA methylation and
gene expression profiling on a panel of 10 paediatric B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) tumours
that were stratified by prednisolone response.
Results: We found high correlations in DNA methylation and gene expression profiles between matching primary and
xenograft tumour samples with Pearson’s correlation coefficients ranging between 0.85 and 0.98. In order to demonstrate
the potential utility of epigenetic analyses in BCP-ALL xenografts, we identified DNA methylation biomarkers
that correlated with prednisolone responsiveness of the original tumour samples. Differential methylation of
CAPS2, ARHGAP21, ARX and HOXB6 were confirmed by locus specific analysis. We identified 20 genes showing an
inverse relationship between DNA methylation and gene expression in association with prednisolone response.
Pathway analysis of these genes implicated apoptosis, cell signalling and cell structure networks in prednisolone
responsiveness.
Conclusions: The findings of this study confirm the stability of epigenetic and gene expression profiles of
paediatric BCP-ALL propagated in mouse xenograft models. Further, our preliminary investigation of prednisolone
sensitivity highlights the utility of mouse xenograft models for preclinical development of novel drug regimens with
parallel investigation of underlying gene expression and epigenetic responses associated with novel drug responses.
Keywords: Acute lymphoblastic leukaemia, Xenografts, Genome-wide DNA methylation, Microarray analysis of gene
expression, Glucocorticoid resistance
* Correspondence: rlock@ccia.unsw.edu.au
†Equal contributors
3Children’s Cancer Institute Australia for Medical Research, Lowy Cancer
Research Centre, UNSW, PO Box 81, Sydney, NSW 2052, Australia
Full list of author information is available at the end of the article
© 2014 Wong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Wong et al. BMC Genomics 2014, 15:416
http://www.biomedcentral.com/1471-2164/15/416
Background
Despite progress in the treatment of several cancers over
recent decades, the lack of clinically relevant tumour
models for individual subtypes of human cancer has
proven to be a major impediment in the development of
effective anti-cancer therapies [1]. Approaches that fa-
cilitate development of novel rational therapies targeting
specific tumours (or specific features of tumours) remain
an urgent priority. Traditional models of human cancer
involving the analysis of immortalised cell lines have
given way in recent years to more clinically relevant
studies in models that mirror the features of primary
tumours [2]. The two main approaches have been the
generation of primary tumour-derived cell lines, and the
generation of mouse models, either via transgenic ap-
proaches or through the engraftment of primary human
tumour into immune-compromised mouse models [3].
Mouse models have been used extensively in this regard,
for preclinical testing of drug efficacy and toxicity prior
to establishing clinical trials. A broad panel of xenografts
with known treatment responsiveness, and well-defined
molecular profiles, would provide an excellent adjunct
to these models [4].
Mouse xenograft models of haematological malignan-
cies, established by the transplantation of donor cells
into non-obese diabetic/severe combined immunodefi-
cient (NOD/SCID) or NOD/SCID/IL-2 receptor gamma
chain−/− (NSG) mice, are recognised as one of the most
clinically relevant systems for investigating leukaemia
biology and testing new treatments [5-12]. This is due to
the faithful recapitulation of many aspects of the human
disease, including kinetics of engraftment in the bone
marrow (BM), with subsequent infiltration of the spleen,
peripheral blood and other organs [10,13,14]. For these
reasons, patient-derived xenografts (PDXs) are consid-
ered superior to in vitro immortalised cancer cell lines
that show many differences to primary tumours, includ-
ing gene expression, drug responsiveness and epigenetic
profiles [15], which is most likely due to the selective
processes associated with long term culturing. PDXs
have become increasingly popular as evidence mounts
that they accurately recapitulate many of the features of
patient tumours, such as tumour microenvironment, dif-
ferentiation state and morphology, architecture and in
some instances molecular signatures of the original pa-
tient tumour (reviewed in [1,2]).
To establish the relevance of PDX models to primary tu-
mours, high density molecular profiling of gene expression
and epigenetic markers should be performed. This was
recently demonstrated for gene expression both between
two tissue types, bone marrow and spleen and between
independently engrafted mice for T-ALL [16].
As a first step towards examining the equivalence of epi-
genetic profiles between primary tumour and xenograft, we
carried out parallel DNA methylation and gene expression
profiling on a panel of childhood B-cell precursor
acute lymphoblastic leukaemia (BCP-ALL) selected by
their clinical responses to prednisolone. This panel con-
sisted of five individuals who had a good response to
prednisolone (PGR) and five who had a poor response
(PPR). By comparing DNA methylation and gene ex-
pression profiles between primary and derived, single-
passaged xenograft lines, we report the stability of both
gene expression and DNA methylation in the xeno-
graft, further highlighting their potential for exploring
gene expression and epigenetic changes associated
with responses to established and novel drugs.
Methods
Patient samples, characteristics and xenograft model
generation
All experimental studies were approved by the Human Re-
search Ethics Committee and the Animal Care and Ethics
Committee of the University of New South Wales. Written
informed consent was obtained from the parents or guard-
ians of paediatric ALL patients for use of biopsy samples in
research, with the exception of samples obtained prior to
May 2003 (ALL-26, ALL-28 and ALL-53), for which a
waiver had been issued by the Human Research Ethics
Committee. A total of 10 xenograft lines were generated
from children diagnosed with BCP-ALL. Individuals were
selected based on their response to prednisolone. We clas-
sified prednisolone poor responders (PPR) as patients with
a peripheral blast count of ≥ 1 × 109/L on day 8 following
induction treatment with prednisolone and a single intra-
thecal dose of methotrexate, while a prednisolone good
responder (PGR) demonstrated a day 8 peripheral blast
count of < 1 × 109/L (Table 1). Xenografts were established
in NOD/SCID or NSG mice using direct explants of patient
BM biopsies, exactly as described previously [10,17].
When mice were highly engrafted with leukaemia
human CD45+, mononuclear cells were isolated from
spleens by FACS at >90% purity and cryopreserved for
subsequent experiments.
Genomic DNA and total RNA extraction
Genomic DNA was extracted from the primary bone mar-
row biopsies used for xenografting and from cells harvested
from the spleens of engrafted animals for each xenograft
using standard phenol/chloroform extraction and isopropa-
nol precipitation. Total RNA was extracted using TriZol
Reagent (Life Technologies, Carlsbad, USA) according to
manufacturer’s instructions. Quality and yield were mea-
sured using a Nanodrop spectrophotometer.
Sodium bisulphite conversion of genomic DNA
Genomic DNA was converted for DNA methylation
analysis using the MethylEasy Xceed Kit (Human Genetic
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Table 1 Patient demographics of xenografts used in this study
Xenograft Sex Age Cytogenetics Immunophenotype Diagnosis WCC Diagnosis blasts Day 8 blasts
(Months) (Diagnostic patient sample) ×109/L ×109/L ×109/L
PPR ALL-28 M 20 Hyperdiploid CD45-/DR+/10+/19+/2-/7-/13-/33+/34+ 15.0 11.8 1.9
PPR ALL-50 M 131 Normal CD45+/DR+/10+/19+/20+ 34.6 26.1 5.5
PPR ALL-54 M 89 Normal CD45+/DR+/10+/19+/20+/34+/13-/33- 185.0 174.8 1.2
PPR ALL-55 M 176 t(9;22) CD45+/DR+/10+/19+/13+/33+/34+ 422.5 388.7 22.6
PPR ALL-57 F 72 t(1;19) CD45+/DR+/19+/10+/34-2-/7- 15.9 7.2 1.6
PGR ALL-26 F 43 t(12;21) CD45+/DR+/CD19+/10+/22+/3-/34+/117-/Cu-/TdT+ 89.4 80.5 0.0
PGR ALL-51 M 19 dic(7;9) CD45+/DR+/CD19+/10+/22+/34-/117-/Cu-/TdT+ 90.5 76.9 0.0
PGR ALL-52 M 138 t(7;15) CD45+/DR+/CD19+/22+/13+/33+/10-/34-/Cu-/TdT+ 14.4 4.0 0.0
PGR ALL-53 M 87 t(12;21) CD45+/DR+/10+/19+/34+ 20.3 13.8 0.1
PGR ALL-56 M 120 t(9;22) CD45-/DR+/10+/19+/34+/2-/7-/13-/33- 8.5 0.1 0.0
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Signatures, Sydney, Australia) according to manufacturer’s
instructions. Converted DNA was used for downstream
Illumina Infinium DNA methylation BeadArray analysis
and SEQUENOM EpitTYPER validation.
Genome-scale DNA methylation analysis
Converted genomic DNA was processed and analysed
for Illumina Infinium HumanMethylation27 BeadArray
(Illumina, San Diego, USA) according to manufacturer’s
instructions (ServiceXS, Leiden, The Netherlands). This
BeadArray platform interrogates 27,578 CpG sites across
the human genome. The arrays were scanned using an
Illumina BeadArray Reader and subsequently processed
using the Illumina GenomeStudio V.1 software package.
The Bioconductor Lumi package was used for down-
stream data processing and normalisation [18]. Briefly,
DNA probe methylation data were quality checked and
then colour balance adjusted, background corrected and
scaled based on the mean of all probes, using the methy-
lation simple scaling normalization (SSN) implemented
within the Lumi package. CpG sites with at least one
sample having a detection p-value > 0.01 were excluded
from subsequent analyses, leaving 27,341 CpG sites. Dif-
ferential methylation analysis was performed using the
LIMMA package from Bioconductor [19]. Significantly
differentially methylated probes were selected based on a
Benjamini-Hochberg adjusted p-value < 0.05. The methy-
lation microarray data have been deposited into Gene
Expression Ominibus (http://www.ncbi.nlm.nih.gov/geo/)
with the identifier GSE57581.
Gene expression Illumina array analysis
Total RNA was extracted from the primary and xenograft
tumours and amplified using the Illumina TotalPrep RNA
amplification kit (Ambion, Austin, USA). The amplified
total RNA was analysed using Illumina WG-6_V3 chips
(Illumina, San Diego, USA) according to manufacturer’s in-
structions. The sample probe profiles with no normalisation
or background correction were exported from BeadStudio
(version 3.0.14, Illumina), and the data were pre-processed
using quantile normalisation. Probes with detection p-value
greater than 0.01 on all arrays were deemed as non-
expressed probes and filtered out. Differential gene
expression was determined using LIMMA with the positive
False Discovery Rate (FDR) correction for multiple testing
(Benjamini-Hochberg adjusted p-value < 0.05). The gene
expression microarray data have been deposited into
Gene Expression Ominibus (http://www.ncbi.nlm.nih.gov/
geo/) with the identifier GSE57491.
SEQUENOM MassArray EpiTYPER analysis
Primers (detailed in Additional file 1: Table S1) were
designed to generate PCR amplicons from bisulphite
converted genomic DNA suitable for SEQUENOM
EpiTYPER chemistry as per the manufacturer’s protocol.
Samples were analysed using MALDI-TOF mass spectrom-
etry, DNA methylation information was collected using
EpiTYPER Viewer Software (v 1.0.5). Non-analysable and
poor quality CpG sites were removed from downstream
analysis as previously described [20].
Results
Xenograft models of BCP-ALL are an accurate reflection
of DNA methylation and gene expression status of the
corresponding primary tumour
One sample in our analysis, ALL28P, failed to meet array
quality metrics (low overall signal intensity). Therefore, the
matching xenograft pair, ALL28X along with ALL28P gene
expression data was removed from subsequent analysis.
ALL28 was also removed from the DNA methylation and
gene expression correlation analysis herein.
Plotting the beta values of the entire data set revealed
similar DNA methylation profiles between primary tumour
tissue and the matching xenograft from each of the 10
patients in our study. Similarly, gene expression levels
between primary tumour tissue and xenograft were also
comparable (Figure 1A). For genome-scale DNA methyla-
tion, Pearson’s correlation coefficients between matching
primary and xenograft samples ranged between 0.94-0.98
while correlation coefficients between individuals ranged
between 0.80-0.91. For genome-wide gene expression,
Pearson’s correlation coefficients between primary and
xenograft samples ranged between 0.85-0.97 and between
individuals was greater than 0.83-0.96 (Figure 1B). Gene
expression profiles between individuals were more corre-
lated than their DNA methylation profiles.
Consistent with this observation, unsupervised hierarch-
ical clustering of the most variable DNA methylation and
gene expression across all samples revealed clustering of
matching primary and xenograft samples. This implies that
the profiles from the xenografts recapitulate the profile of
the primary tumour (Figure 1C).
To identify differential DNA methylation between pri-
mary tumour and matching xenograft samples we ap-
plied a linear model with empirical Bayes estimation and
found 1564 probes to be differentially methylated be-
tween matching primary tumour and xenograft sample
after correction for multiple testing (adjusted p-value <
0.05, Additional file 2: Table S2). The majority of these
probes demonstrated a small change in DNA methylation
with the average difference across individuals ranging from
0.4 to 8.6% (Additional file 3: Figure S1A).
We also looked for differential gene expression be-
tween matching primary and xenograft cell lines again
applying a linear model with empirical Bayes estimation
on the genome-scale gene expression microarray results.
We found 3441 probes from 3208 genes to be differen-
tially expressed between primary and xenograft lines
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Figure 1 (See legend on next page.)
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(adjusted p-value < 0.05, Additional file 4: Table S3).
However, as we observed with DNA methylation, the
differences in expression of these probes between pri-
mary and xenograft were minimal with an average fold
difference in expression between primary and xenograft
tumours of 1.12 (Additional file 3: Figure S1B).
Using DAVID (http://david.abcc.ncifcrf.gov/), the dif-
ferentially methylated and differentially expressed genes
between primary and matching xenograft lines were found
to be mainly involved in haematological and cell signalling
processes that could be accounted for given the cellular ori-
gins of the primary (bone marrow) and xenograft (spleen)
samples.
Given the relatively small number of differentially methyl-
ated probes (6%) and differentially expressed probes (17%),
and the minimal absolute differences in DNA methylation
and expression (Additional file 3: Figure S1A and S1B), our
results indicate that xenograft models largely recapitu-
late the DNA methylation and gene expression profile
of the corresponding primary tumour. This highlights
the potential utility of xenograft cell lines for model-
ling primary disease.
Molecular biomarkers associated with prednisolone
response
We then sought to identify differential DNA methylation
and gene expression associated with prednisolone poor
(PPR) and prednisolone good (PGR) responders and in-
cluded primary and xenograft samples in our analysis.
After correction for multiple testing, 35 DNA methyla-
tion probes were differentially methylated between PPR
and PGR (Benjamini-Hochberg adjusted p-value < 0.05,
Table 2, Figure 2). Gene expression analysis revealed 23
genes differentially expressed between PPR and PGR
(Benjamini-Hochberg adjusted p-value < 0.05, Table 2,
Figure 2). From these lists, we did not find any com-
monly annotated genes associated with prednisolone
response between the top differentially methylated and
top differentially expressed probes. Differential DNA
methylation segregated PPR from PGR by supervised
hierarchical clustering and may serve as potential
biomarkers for prednisolone response (Figure 2A).
However, interrogating gene expression alone did not
accurately segregate PPR from PGR (Figure 2B). Func-
tional annotation of differentially methylated genes
annotated to these probes identified a number of apoptotic,
cell signalling/structure pathways that did not reach statis-
tical significance (Additional file 5: Table S4).
We then determined the relationship between DNA
methylation and gene expression in association with pred-
nisolone response. Plotting the average DNA methylation
and gene expression differences between PPR and PGR re-
vealed 22 probes annotated to 12 genes that were more
highly expressed and less methylated in PPR samples com-
pared to PGR samples (gene expression cut-off greater than
2 and a DNA methylation cut-off of less than −0.2, Figure 3,
Table 3). Conversely, 11 probes annotated to 8 genes were
less highly expressed and more methylated in PPR samples
compared to PPR (gene expression cut-off of less than −2
and a DNA methylation cut-off greater than 0.2, Figure 3,
Table 3). With the exception of expression probes an-
notated to PAWR, MTX2 and MYO3A no other gene
expression and DNA methylation probes reached stat-
istical significance (Table 3). DNA methylation probes
associated with PAWR, MTX2 and MYO3A demon-
strated an average difference of >0.2 between groups
but did not reach significance with LIMMA analysis
between PPR and PGR.
Validation of DNA methylation biomarkers associated
with prednisolone response
From our array analysis, the DNA methylation changes
segregated samples by prednisolone response. We
validated 17 of these probes using SEQUENOM Epi-
TYPER chemistry on both primary and xenograft
samples by selecting from our LIMMA analysis, those also
associated with changes in gene expression (Additional
file 6: Figure S2). Of the assays containing the 17 probes
of interest, 4 regions continued to discriminate samples
according to prednisolone response (Figure 4). These were
associated with the genes CAPS2 and ARHGAP21 (less
methylated in PPR), ARX and HOXB6 (more methylated
in PPR). Primary and matching xenograft samples showed
similar DNA methylation levels in all cases.
Discussion
It is becoming clear that the complexity of genetic,
epigenetic, and subsequent gene expression disruption
associated with human cancer is immense. As such,
many mouse models of tumourigenesis are limited in their
(See figure on previous page.)
Figure 1 Comparisons of DNA methylation and gene expression profiles between primary tumour tissue and xenografts. (A) Scatterplots of
DNA methylation and gene expression array results from ALL26 showing high correlation between primary and xenograft tumours. (B) Heatmap plot of
Pearson’s correlation coefficients of all primary and xenograft samples analysed for DNA methylation and gene expression. Coefficients greater than 0.94
and 0.84 between matching primary and xenograft tumours were observed for DNA methylation and gene expression respectively. (C) Heatmap plot of
the most variable DNA methylation and gene expression probes. A high level of similarity between matching primary and xenograft tumours resulted in
all pairs clustering together. Green Sample Bar depicts PPR, Blue sample Bar depicts PGR.
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Table 2 Differential probes associated with prednisolone response
Probe type Probe ID Gene symbol
Adjusted
p-value ACC DESC
DNA
methylation
probes cg02780988 KRTHA6 0.0001 NM_003771 keratin 36
cg16848873 HOXB6 0.0001 NM_018952 homeobox B6
cg00546897 LOC284837 0.0002 NM_194310
cg02789485 MGC39497 0.0007 NM_152436 GLI pathogenesis-related 1 like 2
cg01605783 LOC284837 0.0010 NM_194310
cg20291222 CAPS2 0.0012 NM_032606 calcyphosine 2
cg05724065 PHKG1 0.0019 NM_006213 phosphorylase kinase, gamma 1 (muscle)
cg00645579 IRF7 0.0033 NM_001572 interferon regulatory factor 7
cg02100629 AMID 0.0158 NM_032797 apoptosis-inducing factor, mitochondrion-associated, 2
cg20649991 LILRB5 0.0170 NM_006840
leukocyte immunoglobulin-like receptor, subfamily B (with
TM and ITIM domains),
member 5
cg11952714 SNX7 0.0170 NM_015976 sorting nexin 7
cg20050826 K6IRS2 0.0170 NM_080747 keratin 72
cg21306775 FLJ44881 0.0190 NM_207461
cg20468883 BNIP2 0.0202 NM_004330 BCL2/adenovirus E1B 19kDa interacting protein 2
cg08739282 DHX15 0.0202 NM_001358 DEAH (Asp-Glu-Ala-His) box polypeptide 15
cg03172991 NFIX 0.0211 NM_002501 nuclear factor I/X (CCAAT-binding transcription factor)
cg19238840 GP2 0.0211 NM_001007240 glycoprotein 2 (zymogen granule membrane)
cg10148841 ROBO4 0.0223 NM_019055 roundabout homolog 4, magic roundabout (Drosophila)
cg09892390 ARHGAP21 0.0254 NM_020824 Rho GTPase activating protein 21
cg05961212 ADPRH 0.0254 NM_001125 ADP-ribosylarginine hydrolase
cg22844623 GJA12 0.0254 NM_020435 gap junction protein, gamma 2, 47kDa
cg18096388 PDCD1 0.0255 NM_005018 programmed cell death 1
cg05921324 APOA4 0.0255 NM_000482 apolipoprotein A-IV
cg13633560 LRRC32 0.0270 NM_005512 leucine rich repeat containing 32
cg19573166 SLC22A17 0.0270 NM_020372 solute carrier family 22, member 17
cg01410472 CRISPLD1 0.0277 NM_031461 cysteine-rich secretory protein LCCL domain containing 1
cg26624914 AQP3 0.0377 NM_004925 aquaporin 3 (Gill blood group)
cg23752985 VAMP8 0.0389 NM_003761 vesicle-associated membrane protein 8 (endobrevin)
cg21148892 CLEC4F 0.0389 NM_173535 C-type lectin domain family 4, member F
cg00032666 CXorf6 0.0402 NM_005491 mastermind-like domain containing 1
cg19511844 ORMDL3 0.0418 NM_139280 ORM1-like 3 (S. cerevisiae)
cg16127900 GPRC6A 0.0466 NM_148963 G protein-coupled receptor, family C, group 6, member A
cg12552392 NFS1 0.0475 NM_181679
cg22437699 ARX 0.0479 NM_139058 aristaless related homeobox
cg02849695 CCDC19 0.0486 NM_012337 coiled-coil domain containing 19
Gene expression
probes ILMN_1806907 PAWR 0.0000 NM_002583 PRKC, apoptosis, WT1, regulator
ILMN_1794046 MTX2 0.0119
NM_006554
NM_001006635 Metaxin 2
ILMN_1758128 CYGB 0.0119 NM_134268 Cytoglobin
ILMN_1738438 MAST4 0.0157 NM_198828 Microtubule associated serine/threonine kinase family
member 4
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capacity to faithfully mimic human disease. In light of this,
patient derived tumour tissue xenograft models are increas-
ingly recognised as offering the most robust approach for
testing tumour responses to various chemotherapeutic
regimens, evaluating the efficacy of novel therapeutic
agents, analysing the process of tumour progression at
the cellular and molecular level and the identification of
new therapeutic targets [2]. However, as with most mouse
xenograft models, the stability of molecular profiles (gene
expression and epigenetic) that regulate all aspects of
Table 2 Differential probes associated with prednisolone response (Continued)
ILMN_1789384 QSOX2 0.0190 NM_181701 Quiescin Q6 sulfhydryl oxidase 2
ILMN_2306565 MTX2 0.0190
NM_006554
NM_001006635 Metaxin 2
ILMN_2295987 NBPF1 0.0237 NM_017940 Neuroblastoma breakpoint family, member 1
ILMN_1765772 MYO3A 0.0305 NM_017433 Myosin IIIA
ILMN_1713934 LITAF 0.0305 NM_004862 Lipopolysaccharide-induced TNF factor
ILMN_1668125 MYRIP 0.0305 NM_015460 Myosin VIIA and Rab interacting protein
ILMN_1681888 PRKAR2A 0.0305 NM_004157 Protein kinase, cAMP-dependent, regulatory, type II, alpha
ILMN_2184966 ZHX2 0.0305 NM_014943 Zinc fingers and homeoboxes 2
ILMN_1706505 COL5A1 0.0305 NM_000093 Collagen, type V, alpha 1
ILMN_1656057 PLAU 0.0305 NM_002658 Plasminogen activator, urokinase
ILMN_1761540 SEMA3F 0.0305 NM_004186
Sema domain, immunoglobulin domain (Ig), short basic
domain, secreted, (semaphorin) 3F
ILMN_1753143 DKFZp761L1918 0.0305 NM_033103 Homo sapiens rhophilin-like protein mRNA, complete cds.
ILMN_2148944 ADCY4 0.0305 NM_139247 Adenylate cyclase 4
ILMN_1812618 ARAP3 0.0305 NM_022481 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3
ILMN_1681081 AGPAT2 0.0359 NM_006412
1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophospha-
tidic acid acyltransferase, beta)
ILMN_1743275 SH3RF3 0.0359 NM_001099289 SH3 domain containing ring finger 3
ILMN_1656951 APCDD1 0.0359 NM_153000 Adenomatosis polyposis coli down-regulated 1
ILMN_1719756 ZAP70 0.0359
NM_207519
NM_001079 Zeta-chain (TCR) associated protein kinase 70kDa
ILMN_1768732 SPAG16 0.0437
NM_024532
NM_001025436 Sperm associated antigen 16
A B
Figure 2 Heatmap plot of the most significant DNA methylation and gene expression probes distinguishing prednisolone good
responders (PGR) from poor responders (PPR) after LIMMA analysis (BH adjusted p-value < 0.05). DNA methylation probes distinguished
PGR from PPR while gene expression probes did not.
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tumour function remains to be determined. Confirmation
of this stability is crucial in order identify molecular re-
sponses to treatment within the xenograft that could be ex-
trapolated back to patients.
Here, we have determined the stability of genome wide
DNA methylation and gene expression profiles between
primary tumour cells and matching xenograft tumour
cells from a small number of paediatric ALL cases with
differential response to prednisolone. A high correlation
in both DNA methylation and gene expression profiles
was observed in all cases, confirming the stability of these
molecular features of primary tumours in the mouse sys-
tem. Differences in DNA methylation and gene expression
between primary and xenograft samples were negligible in
magnitude (Additional file 3: Figure S1) and comprised of a
small fraction of probes for each array platform. The
differentially methylated genes include MYOD1, GPR6 and
SLC27A6 (Table 1). Many genes associated with minor ex-
pression differences were part of the globin gene family and
genes involved in oxygen transport and include HBB,
AHSP, HBD, HBA2 (Table 2). This is likely to have arisen
by the differences in cellular composition as the primary
tumour samples contained a milieu of haematopoietic cells,
including human erythrocytes that were absent in the
xenograft samples that comprised of mononuclear
cells derived from the murine spleen. Given the high
degree of correlation and clustering of matching primary
and xenograft samples after unsupervised hierarchical
clustering of the most varied probes for DNA methyla-
tion and gene expression, the xenografts described in
this study are an accurate reflection of their corresponding
primary tumours.
While a number of candidate genes whose DNA methy-
lation and/or gene expression status were associated with
prednisolone response, given the small sample numbers
and inherent genetic heterogeneity of the tumours, the
significance of these genes remains unclear. Using
hierarchical clustering, the most significant probes for
DNA methylation discriminated prednisolone response
while the gene expression probes did not (Figure 2),
reflecting the more variable nature of gene expression com-
pared to DNA methylation [21,22]. Using SEQUENOM,
we were able to replicate DNA methylation changes at four
genes associated with prednisolone response indicative of a
potential DNA methylation biomarker. Taking methylation
and expression status together, 20 genes were differentially
regulated between good and poor responders to prednis-
olone (Table 3). While the genes were found to be part
of apoptotic and cell signalling pathways, their signifi-
cance remains unclear given the small numbers in each
group. PAWR demonstrated significant overexpression
and hypomethylation across PPRs compared to PGRs.
This is a WT1 interacting protein that also functions as
a transcriptional repressor with pro-apoptotic func-
tions and tumour resistance [23]. While the down
regulation of PAWR confers poor prognosis in a range
−0.4 −0.2 0.0 0.2 0.4
−
4
−
2
0
2
4
Avg Beta PPR−PGR
Av
g 
Lo
g2
 P
PR
−P
G
R
PAWR
ANXA5
CRMP1
CYB5R2
ANXA5
VLDLR
POU4F1
MYO3A
PAWR
MPO
ARHGAP21
CTSC
CTSC
CTSC
LDOC1
H2AFY2
CTSC
CTSC
ARHGAP21MTX2
MTX2
LDOC1
CRMP1
MYO3A
TNS3
Figure 3 Scatterplot of the average DNA methylation and gene expression difference between PPR and PGR samples reveals 20 genes
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of solid tumours [24,25], its role in haematological malig-
nancy is less clear, with expression detectable in a range of
leukaemias [26]. Our results warrant further investigation
of PAWR to determine a potential role in prednisolone
response and responses to other novel drug regimens in
an expanded xenograft cohort.
Another gene with potential interest is POU4F1,
which appears to be differentially regulated according
Table 3 Probes both differentially methylated and expressed in association with prednisolone response
Expression Methylation
Threshold Gene_symbol.x Gene_description.x adj.P.Val adj.P.Val methDiff expDiff
Upregulated and less methylated
in PPR H2AFY2 H2A histone family, member Y2 0.1173 0.1782 -0.2204 4.0116
(>2-fold expression, <-0.2
methylation) H2AFY2 H2A histone family, member Y2 0.1173 0.3973 -0.3007 4.0116
MTX2 Metaxin 2 0.0190 0.3673 -0.4061 3.9695
PAWR PRKC, apoptosis, WT1, regulator 0.0000 0.3154 -0.4185 3.6350
PAWR PRKC, apoptosis, WT1, regulator 0.0000 0.3973 -0.3026 3.6350
MYO3A Myosin IIIA 0.0305 0.2944 -0.4156 3.4893
MYO3A Myosin IIIA 0.0305 0.3154 -0.4006 3.4893
MTX2 Metaxin 2 0.0119 0.3673 -0.4061 3.1908
BX537570 0.2492 0.0333 -0.3571 3.1574
BX537570 0.2492 0.1707 -0.4761 3.1574
CTSC Cathepsin C 0.0624 0.1782 -0.4239 2.6472
CTSC Cathepsin C 0.0624 0.2267 -0.2834 2.6472
CTSC Cathepsin C 0.0766 0.1782 -0.2834 2.5574
CTSC Cathepsin C 0.0766 0.2267 -0.4239 2.5574
MOSC1
MOCO sulphurase C-terminal domain
containing 1 0.0578 0.5189 -0.2051 2.5035
NGFRAP1
Nerve growth factor receptor
(TNFRSF16) associated protein 1 0.4360 0.4775 -0.2504 2.4066
MARCKS
Myristoylated alanine-rich protein
kinase C substrate 0.5467 0.4154 -0.2603 2.3418
MPO Myeloperoxidase 0.5920 0.4097 -0.2226 2.3130
CTSC Cathepsin C 0.0578 0.1782 -0.2834 2.1699
CTSC Cathepsin C 0.0578 0.2267 -0.4239 2.1699
CCR7 Chemokine (C-C motif) receptor 7 0.2918 0.4434 -0.2264 2.0570
PLS3 Plastin 3 (T isoform) 0.6662 0.3610 -0.2919 2.0256
Downregulated and more
methylated in PPR POU4F1 POU class 4 homeobox 1 0.1004 0.4404 0.3017 -5.3928
(<-2-fold expression, >0.2
methylation) CYB5R2 Cytochrome b5 reductase 2 0.1734 0.5066 0.2699 -4.3486
TMED6
Transmembrane emp24 protein
transport domain containing 6 0.0504 0.5271 0.2317 -4.1584
CRMP1 Collapsin response mediator protein 1 0.3007 0.4431 0.3668 -3.8640
CRMP1 Collapsin response mediator protein 1 0.3007 0.3996 0.2607 -3.8640
IRX3 Iroquois homeobox 3 0.5401 0.4957 0.2710 -2.9003
LDOC1
Leucine zipper, down-regulated
in cancer 1 0.2608 0.6055 0.2578 -2.4859
DSC3 Desmocollin 3 0.5401 0.4585 0.3377 -2.2248
DSC3 Desmocollin 3 0.5401 0.4402 0.3561 -2.2248
ANXA5 Annexin A5 0.5923 0.3699 0.2228 -2.0708
ANXA5 Annexin A5 0.5923 0.3727 0.2386 -2.0708
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to prednisolone response (Table 3). However in our
analysis, statistical significance was not achieved with
the modest sample size of our panel. POU4F1 has been
shown to have a role in regulating the expression of
B-cell markers in t(8;21) positive acute myeloid leukae-
mia [27-29]. Its role in B-cell ALL response to prednis-
olone remains unclear and could be a potential gene target
for further characterisation in an expanded B-cell ALL
xenograft panel.
While our study did not identify statistically signifi-
cant genes associated with prednisolone response, we
present here a first pass analysis using low-resolution
microarray platforms to interrogate DNA methylation
and gene expression across our model system. We
demonstrate that our B-cell ALL xenograft panel reca-
pitulates the DNA methylation and gene expression
profiles of the primary tumour and will facilitate future
genome-wide interrogation of gene expression and
DNA methylation using next generation sequencing
methodology.
Conclusions
Patient-derived tumour xenograft models offer superior
utility as preclinical models over cell line systems with their
ability to recapitulate the milieu and microenvironment of
the primary tumour. However, the extent of gene expres-
sion and epigenetic stability within the xenograft has
remained unclear at least in the haematological setting.
We have demonstrated that the gene expression and
DNA methylation profiles of cells taken from the
spleens of engrafted mice are highly correlated to the
original primary tumour. Given the similarity to the
primary tumour, our study confirms the opportunity to
investigate gene expression and DNA methylation bio-
markers in response to novel treatment strategies.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files. All micro-
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